Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma
Tao Xia,
Chi Cheng,
Yudi Meng,
Hao Huang,
Duo Li,
Renfan Zhu,
Chengcong Qiu,
Yongfei Hua Cancer Medicine
· Wiley
· 2026-11-05
· DOI: 10.1002/cam4.72491
The publisher did not provide an abstract — full text is available via the link below.
Tao Xia, Chi Cheng, Yudi Meng, Hao Huang, Duo Li, Renfan Zhu et al. Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma. // Cancer Medicine. – 2026. – DOI: 10.1002/cam4.72491. – URL: https://onlinelibrary.wiley.com/doi/10.1002/cam4.72491?af=R
Tao Xia, Chi Cheng, Yudi Meng, Hao Huang, Duo Li, Renfan Zhu, Chengcong Qiu, & Yongfei Hua (2026). Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.72491
Tao Xia, et al. “Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma.” Cancer Medicine, 2026. doi:10.1002/cam4.72491.
@article{Xia2026,
title = {Factors Associated With Recurrence After Adjuvant Gemcitabine and Nab‐Paclitaxel in Patients With Resected Pancreatic Ductal Adenocarcinoma},
author = {Xia, Tao and Cheng, Chi and Meng, Yudi and Huang, Hao and Li, Duo and Zhu, Renfan and Qiu, Chengcong and Hua, Yongfei},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72491},
url = {https://onlinelibrary.wiley.com/doi/10.1002/cam4.72491?af=R}
}